We are live on
!
Find out more
Acadian Asset Management Portfolio holdings
AUM
$70.5B
1-Year Est. Return
36%
This Fund
S&P 500
This Quarter
Est. Return
+1.38%
1 Year Est. Return
+36%
3 Year Est. Return
+137.96%
5 Year Est. Return
+215.76%
10 Year Est. Return
+864.44%
AUM
$23.9B
AUM Growth
-$469M
(-1.9%)
Cap. Flow
-$145M
Cap. Flow
% of AUM
-0.61%
Top 10 Holdings %
Top 10 Hldgs %
20.52%
Holding
1,935
New
209
Increased
532
Reduced
683
Closed
293
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stellantis
STLA
|
+$392M |
| 2 |
BP
BP
|
+$158M |
| 3 |
General Motors
GM
|
+$152M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$148M |
| 5 |
Amdocs
DOX
|
+$104M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$102M |
| 2 |
Marriott International
MAR
|
+$95.6M |
| 3 |
Fortinet
FTNT
|
+$94.9M |
| 4 |
Cardinal Health
CAH
|
+$91.3M |
| 5 |
Apple
AAPL
|
+$88.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.31% |
| 2 | Consumer Discretionary | 13.19% |
| 3 | Healthcare | 10.9% |
| 4 | Consumer Staples | 10.22% |
| 5 | Communication Services | 9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1226
Werewolf Therapeutics
HOWL
$19.2M
| $167K | ﹤0.01% |
78,671
| – | – |
|
1227
Teradyne
TER
$61.9B
| $167K | ﹤0.01% |
+1,671
| New | +$176K |
|
1228
Pool Corp
POOL
$7.27B
| $166K | ﹤0.01% |
471
-73
| -13% | -$26.6K |
|
1229
PTC
PTC
$16.1B
| $166K | ﹤0.01% |
1,172
| – | – |
|
|
IRD
1230
Opus Genetics
IRD
$322M
| $165K | ﹤0.01% |
49,563
+21,318
| +75% | +$85.6K |
|
1231
Baidu
BIDU
$35.3B
| $164K | ﹤0.01% |
1,224
-333
| -21% | -$46.7K |
|
|
CGAU
1232
Centerra Gold
CGAU
$4.33B
| $163K | ﹤0.01% |
33,428
-676,121
| -95% | -$3.96M |
|
1233
First United
FUNC
$295M
| $162K | ﹤0.01% |
10,106
| – | – |
|
1234
FS KKR Capital
FSK
$3.38B
| $161K | ﹤0.01% |
8,225
+8,220
| +164,400% | +$164K |
|
1235
Alnylam Pharmaceuticals
ALNY
$29.4B
| $160K | ﹤0.01% |
904
+311
| +52% | +$59.3K |
|
1236
PDF Solutions
PDFS
$2.19B
| $158K | ﹤0.01% |
4,885
-20,625
| -81% | -$790K |
|
1237
Carnival Corporation Ltd
CCL
$38.1B
| $156K | ﹤0.01% |
11,402
+9,934
| +677% | +$165K |
|
|
BLPH
1238
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $152K | ﹤0.01% |
383,178
+117,925
| +44% | +$58.1K |
|
1239
Energy Transfer Partners
ET
$71.6B
| $151K | ﹤0.01% |
10,815
-2,383
| -18% | -$31.6K |
|
1240
Q32 Bio
QTTB
$456M
| $151K | ﹤0.01% |
7,225
-5,722
| -44% | -$117K |
|
1241
Nuvation Bio
NUVB
$2.24B
| $150K | ﹤0.01% |
113,717
+82,031
| +259% | +$137K |
|
|
AIOS
1242
AIOS Tech
AIOS
$43.6M
| $149K | ﹤0.01% |
3,137
| – | – |
|
1243
Monster Beverage
MNST
$88.5B
| $148K | ﹤0.01% |
5,616
-3,208
| -36% | -$91.2K |
|
1244
RTX Corp
RTX
$298B
| $146K | ﹤0.01% |
2,051
-7,316
| -78% | -$627K |
|
1245
Service Corp International
SCI
$11.2B
| $146K | ﹤0.01% |
2,560
-1,461
| -36% | -$92.3K |
|
1246
Virco
VIRC
$92.6M
| $146K | ﹤0.01% |
+18,637
| New | +$89.3K |
|
1247
Spyre Therapeutics
SYRE
$9.03B
| $145K | ﹤0.01% |
11,888
-43,767
| -79% | -$579K |
|
1248
Arq
ARQ
$99.1M
| $145K | ﹤0.01% |
81,979
-106,029
| -56% | -$207K |
|
1249
Korn Ferry
KFY
$4.21B
| $144K | ﹤0.01% |
3,040
-33,074
| -92% | -$1.68M |
|
1250
Lifeway Foods
LWAY
$458M
| $143K | ﹤0.01% |
+13,942
| New | +$121K |
|
Similar funds
BC
Acadian Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, Acadian Asset Management held 1,935 positions worth $23.9B, down 1.9% from $24.3B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Acadian Asset Management's Q3 2023 filing shows 209 new, 532 increased, 683 reduced and 293 closed positions. Its largest new stake was Amdocs: 1,147,499 shares worth $96.9M. The largest sale was GSK, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 29% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Acadian Asset Management's largest Q3 2023 buy was Amdocs: 1,147,499 shares worth $96.9M.
- Acadian Asset Management added most to Stellantis in Q3 2023, an estimated $392M increase.
- Acadian Asset Management's biggest Q3 2023 reduction was GSK, cutting an estimated $102M.
- Acadian Asset Management fully exited KE Holdings in Q3 2023, selling an estimated $49.5M.
- Acadian Asset Management's ten largest holdings make up 21% of its $23.9B portfolio in Q3 2023.
- Acadian Asset Management opened 209 new positions and closed 293 in Q3 2023.
- Acadian Asset Management's portfolio value fell 1.9% quarter-over-quarter to $23.9B.
Based on Acadian Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.